From Subtle Signs to Significant Impact: Identifying TD in Your Patients
In this video, PA Williams delves into the crucial process of screening and diagnosing Tardive Dyskinesia (TD). The video emphasizes the need for comprehensive medical histories, frequent monitoring using the Abnormal Involuntary Movement Scale (AIMS), and understanding the diagnostic criteria outlined in the DSM-5. He also clarifies the distinction between TD and drug-induced parkinsonism, as differential diagnosis is vital for appropriate treatment.
Key Takeaways:
- Frequent monitoring, including AIMS, of patients who are at risk for Tardive Dyskinesia (TD) is critical.
- It is important to be able to distinguish between TD and drug-induced parkinsonism because treatment is different.
Speaker
Click on the photo below to learn more about the speaker.
References and Additional Resources:
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5 (R)). 5th ed. American Psychiatric Association Publishing; 2013.
Caroff SN. A new era in the diagnosis and treatment of tardive dyskinesia. CNS Spectr. 2023;28(4):401-415. doi:10.1017/S1092852922000992
Caroff SN, Citrome L, Meyer J, et al. A modified Delphi consensus study of the screening, diagnosis, and treatment of tardive dyskinesia. J Clin Psychiatry. 2020;81(2). doi:10.4088/JCP.19cs12983
Hauser RA, Meyer JM, Factor SA, et al. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr. 2022;27(2):208-217. doi:10.1017/s109285292000200x
Kane JM, Correll CU, Nierenberg AA, Caroff SN, Sajatovic M, Tardive Dyskinesia Assessment Working Group. Revisiting the Abnormal Involuntary Movement Scale: Proceedings from the tardive dyskinesia assessment workshop. J Clin Psychiatry. 2018;79(3). doi:10.4088/JCP.17cs11959
Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39(4):486-487. doi:10.1001/archpsyc.1982.04290040080014
Supported by
